Features | Partner Sites | Information | LinkXpress
Sign In
RANDOX LABORATORIES
FOCUS DIAGNOSTICS, INC.
GLOBETECH PUBLISHING LLC

Biomarker Improves Head and Neck Cancer Patient Prognosis

By Labmedica International staff writers
Posted on 31 Jan 2012
A molecular fingerprint in head and neck cancers can predict whether a patient's tumor will be life threatening.

The molecular fingerprint biomarker is considered particularly promising because it can detect the level of risk immediately following diagnosis. This biomarker could become a component of a new test to guide how aggressively those with head and neck tumors should be treated.

A study was performed at Albert Einstein College of Medicine of Yeshiva University (Bronx, NY, USA) and Montefiore Medical Center (Bronx, NY, USA), the University Hospital for Einstein. Tissue samples were taken from tumors and nearby healthy tissue of 123 head and neck cancer patients at Montefiore and levels of 736 microRNAs were measured. Of all the microRNAs measured, one in particular–miR-375– stood out for being the most down-regulated in head and neck tumors compared with its levels in adjacent normal tissue.

The 123 patients were ranked according to how extreme the difference was between the miR-375 in their tumor and in adjacent normal tissue, with that difference expressed as the ratio: miR-375 level in patient's tumor tissue divided by miR-375 level in patient's normal tissue. All patients were then followed throughout the course of their illness.

MiR-375 proved to be a highly useful biomarker for predicting disease outcome. The patients for whom the difference between their tumor and normal-tissue miR-375 levels was most extreme (i.e., the one-fourth of patients with the lowest ratios) were nearly 13 times more likely to die or 9 times more likely to experience distant spread (metastasis) of their cancer compared to patients with higher miR-375 ratios.

The findings were published online January 9, 2012, in the American Journal of Pathology.

Related Links:

Albert Einstein College of Medicine
Montefiore Medical Center


CELLAVISION AB
KARL HECHT GMBH & CO KG
MEDLAB Asia

Channels

Industry News

view channel
Image: Positive case of lung tissue stained for ALK with VENTANA ALK (D5F3) CDx Assay, a companion diagnostic immunohistochemical test in the final stages of the FDA premarket approval process (Photo courtesy of Ventana Medical Systems and PRNewsFoto).

Premarket Approval Sought for CDx Test to Benefit Lung Cancer Patients

Ventana Medical Systems, Inc. (Tucson, AZ, USA) has announced its US Food & Drug Administration (FDA) final stage submission for premarket approval (PMA) of its companion diagnostic (CDx) immunohistochemistry... Read more
 

Events

05 Mar 2015 - 08 Mar 2015
18 Mar 2015 - 20 Mar 2015
Copyright © 2000-2015 Globetech Media. All rights reserved.